MaxCyte, Inc. Common Stock
MXCTStock
$1.35−32.70%52W
Market Cap$154.49M
P/E—
Div yield—
Beta1.48
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-15.42%
Price vs S&P 500 (4W)23.96%
VGM Score43.78
Market Capitalization$154.49M
Earnings Surprise History
Q1 26-0.04est. -0.08
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.15
4.15
4.15
4.15
Industry Peers — R&D — Physical Sciences(15)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MXCTMaxCyte, Inc. Common Stock | C | D | B | $1.35 |
| IQVIQVIA Holdings Inc. | C | C | B | $210.49 |
| INCYIncyte Genomics Inc | C | A | B | $116.65 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | $537.92 |
| ICLRIcon Plc | C | C | B | $170.00 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $229.16 |
| ABSIAbsci Corporation Common Stock | F | F | A | $8.23 |
| NRCNRC Health Common Stock | D | D | B | $21.94 |
| OABIOmniAb, Inc. Common Stock | D | C | B | $2.04 |
| ONMDOneMedNet Corp Class A Common Stock | D | C | C | $0.69 |
| BIAFbioAffinity Technologies, Inc. Common Stock | A | F | F | $0.71 |
About
MaxCyte Inc is a commercial cell engineering company that develops and commercializes technologies for the discovery and development of next-generation cell therapeutics. The company's proprietary Flow Electroporation platform enables the efficient engineering of diverse cell types for therapeutic and research applications. MaxCyte generates revenue from the sale and licensing of its instruments and related single-use disposable processing assemblies.